Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,381
datasets available to search
ShareScore release 0.9.0
Dataset results
1,381 results for “Metastatic tumors”
Dataset of "TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth"
<p>The embryonic transcription factors TWIST1/2 are frequently overexpressed in cancer, acting as multifunctional oncogenes. Here we investigate their role in neuroblastoma (NB), a heterogeneous childhood malignancy ranging from spontaneous regression to dismal outcomes despite multimodal therapy. We first reveal the association of TWIST1 expression with poor survival and metastasis in primary NB, while TWIST2 correlates with good prognosis. Secondly, suppression of TWIST1 by CRISPR/Cas9 results in a reduction of tumor growth and metastasis in immunocompromised mice. Moreover, TWIST1 knock-out tumors displays a less aggressive cellular morphology and a reduced disruption of the extracellular matrix (ECM) reticulin network. Additionally, we identify a TWIST1-mediated transcriptional program associated with dismal outcome in NB and involved in the control of pathways mainly linked to the signaling, migration, adhesion, the organization of the ECM, and the tumor cells versus tumor stroma crosstalk. Taken together, our findings identified TWIST1 as novel therapeutic target in NB.</p>
Dataset for "TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth"
<p>The embryonic transcription factors TWIST1/2 are frequently overexpressed in cancer, acting as multifunctional oncogenes. Here we investigate their role in neuroblastoma (NB), a heterogeneous childhood malignancy ranging from spontaneous regression to dismal outcomes despite multimodal therapy. We first reveal the association of TWIST1 expression with poor survival and metastasis in primary NB, while TWIST2 correlates with good prognosis. Secondly, suppression of TWIST1 by CRISPR/Cas9 results in a reduction of tumor growth and metastasis in immunocompromised mice. Moreover, TWIST1 knock-out tumors displays a less aggressive cellular morphology and a reduced disruption of the extracellular matrix (ECM) reticulin network. Additionally, we identify a TWIST1-mediated transcriptional program associated with dismal outcome in NB and involved in the control of pathways mainly linked to the signaling, migration, adhesion, the organization of the ECM, and the tumor cells versus tumor stroma crosstalk. Taken together, our findings confirm TWIST1 as promising therapeutic target in NB.</p> <p>This dataset comprise images (.ndpi files) of anti-F4/80 IHC staining used for the quantification of macrophages in subcutaneous and orthotopic neuroblastoma xenografts derived from SK-N-Be2c cells expressing TWIST1 or knocked out for TWIST1 through CRISR/Cas9.</p>
Tumor-Immune Microenvironment Revealed by Imaging Mass Cytometry in a Metastatic Sarcomatoid Urothelial Carcinoma with a Prolonged Response to Pembrolizumab - IMC data
<blockquote> <p>Sarcomatoid urothelial carcinoma (SUC) is a rare subtype of urothelial carcinoma (UC), that typically presents at an advanced stage compared to more common variants of UC. Locally advanced and metastatic UC have a poor long-term survival following progression on first-line platinum-based chemotherapy. Antibodies directed against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) are now approved to be used in these scenarios. The need for reliable biomarkers for treatment stratification is still under research. Here we present a novel case report of the first Image Mass Cytometry (IMC) analysis done in SUC to investigate the immune cell repertoire and PD-L1 expression in a patient who presented with metastatic SUC and experienced a prolonged response to the anti-PD1 immune checkpoint inhibitor pembrolizumab after progression on first line chemotherapy. This case report provides an important platform for translating these findings to a larger cohort of UC and UC variants.</p> </blockquote> <p>We make available TIFF files containing imaging mass cytometry data for 4 regions of interest of a sample of metastatic sarcomatoid urothelial carcinoma. The order of the axis in the image stacks is "CYX". The CSV files indicate the identity of the channels.</p>
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
ClinicalTrials.gov study NCT04381650. IPD Sharing: YES. Countries: 9. Publications: 1.
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
ClinicalTrials.gov study NCT03085914. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
ClinicalTrials.gov study NCT04157517. IPD Sharing: YES. Countries: 2. Publications: 1.
Effect of Digoxin on clusters of circulating tumor cells in patients with metastatic breast cancer: a phase 1 trial
<p>This repository contains processed transcriptomics data, large data sets and additional files required to reproduce the code available at the repository https://github.com/TheAcetoLab/dicct-trial</p>
Raw Data for the article: Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion
<p>Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our knowledge on the fifth candidate renamed now miR-CT3. MiR-CT3 expression was low in OS cells when compared with human primary osteoblasts and healthy bone. Through TargetScan, VEGF-A was predicted as a potential biological target of miR-CT3 and luciferase assay confirmed it. We showed that enforced expression of miR-CT3 in two OS cell lines, SAOS-2 and MG-63, reduced expression of VEGF-A mRNA and protein, inhibiting tumor angiogenesis. Enforced expression of miR-CT3 also reduced OS cell migration and invasion as confirmed by soft agar colony formation assay. Interestingly, we found that miR-CT3 behaves inducing the activation of p38 MAP kinase pathway and modulating the epithelial-mesenchymal transition (EMT) proteins, in particular reducing Vimentin expression. Overall, our study highlights the novel role of miR-CT3 in regulating tumor angiogenesis and progression in OS cells, linking also to the modulation of EMT proteins.</p>
All datasets of primary tumors, primary or metastatic sites of metastatic tumors used in this study
<p>All datasets of primary tumors, primary or metastatic sites of metastatic tumors used in this study</p>
CXCL12-loaded-hydrogel (CLG): a new device for metastatic Circulating Tumor Cells (CTCs) capturing and characterization
<p><strong>Background</strong>: Circulating Tumor Cells (CTCs) represent a small, heterogeneous population that comprise the minority of cells able to develop metastasis. To trap and characterize CTCs with metastatic attitude, a CXCL12-loaded hyaluronic-gel (CLG) was developed. CXCR4+cells with invasive capability would infiltrate CLG.<br><strong>Methods</strong>: Human colon, renal, lung and ovarian cancer cells (HT29, A498, H460 and OVCAR8 respectively) were seeded on 150 µl Empty Gels (EG) or 300 ng/ml CXCL12 loaded gel (CLG) and allowed to infiltrate for 16 hours. Gels were then digested and fixed with 2% FA-HAse for human cancer cell enumeration or digested with HAse and cancer cells recovered. CLG-recovered cells migrated toward CXCL12 and were tested for colonies/spheres formation. Moreover, CXCR4, E-Cadherin and Vimentin expression was assessed through flow cytometry and RT-PCR. The clinical trial “TRAP4MET” recruited 48 metastatic/advanced cancer patients (8 OC, 8 LC, 8 GBM, 8 EC, 8 RCC and 8 EC). 10 cc whole blood were devoted to PBMCs extraction (7cc) and ScreenCell™ filters (3cc) CTCs evaluation. Ficoll-isolated patient’s PBMCs were seeded over CLG and allowed to infiltrate for 16 hours; gels were digested and fixed with 2% FA-HAse, cells stained and DAPI+/CD45-/pan-CK+ cells enumerated as CTCs.<br><strong>Results</strong>: Human cancer cells infiltrate CLG more efficiently than EG (CLG/EG ratio 1.25 for HT29/ 1.58 for A498/ 1.71 for H460 and 2.83 for OVCAR8). CLG- recovered HT29 cells display hybrid-mesenchymal features [low E-cadherin (40%) and high vimentin (235%) as compared to HT29], CXCR4 two-fold higher than HT29, efficiently migrate toward CXCL12 (two-fold higher than HT29) and developed higher number of colonies (171±21 for HT29-CLG vs 131±8 colonies for HT29) /larger spheres (spheroid area: 26561±6142 µm2 for HT29-CLG vs 20297±7238 for HT29). In TRAP4MET clinical trial, CLG-CTCs were isolated in 8/8 patients with OC, 6/8 with LC, 6/8 with CRC, 8/8 with EC, 8/8 with RCC cancer and 5/8 with GBM. Interestingly, in OC, LC and GBM, CLG isolated higher number of CTCs as compared to the conventional ScreenCell™ (CLG/SC ratio=1.88 for OC, 2.47 for LC and 11.89 for GBM). Bland and Altman blot analysis and Passing and Bablok regression analysis showed concordance between the methodological approaches but indicate that SC and CLG are not superimposable suggesting that the two systems select cells with different features.<br><strong>Conclusion</strong>: CLG might represent a new and easy tool to isolate invasive CTCs in multiple cancers such as OC, LC and GBM at today orphan of reliable methods to consistently detect CTCs. </p>
Data to reproduce analysis in the WCDT metastatic prostate tumor subtypying paper
<p>Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation AR-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration resistant prostate cancer (mCRPC), defined by whether the tumor expresses either AR or neuroendocrine markers. Among the subtypes of mCRPC, the molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterize genomic and epigenomic features of treatment-emergent mCRPC subtypes in 210 tumors by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing. We show that AR-/NE- tumors exhibit a clinically and molecularly distinct phenotype. Patients with AR-/NE- mCRPC tumors have the shortest survival, and these tumors preferentially harbor amplification of the chromatin remodeler <em>CHD7</em> and loss of <em>PTEN</em>. We demonstrate that methylation changes in <em>CHD7</em> candidate enhancers are linked to elevated <em>CHD7</em> expression in AR-/NE+ tumors. Moreover, we use genome-wide methylation analysis to nominate the Krüppel-like factor gene <em>KLF5</em> as a driver of the AR-/NE- phenotype and link its activity to loss of the tumor supressor <em>RB1</em>. These observations reveal the aggressiveness of the AR-/NE- tumors and elucidate genomic and epigenomic drivers of mCRPC subtypes, which may facilitate the identification of novel therapeutic targets in this highly aggressive disease.</p>
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
ClinicalTrials.gov study NCT02360579. IPD Sharing: NO. Countries: 8. Publications: 4.
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
ClinicalTrials.gov study NCT02784795. IPD Sharing: Not stated. Countries: 4. Publications: 2.
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
ClinicalTrials.gov study NCT02923349. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
ClinicalTrials.gov study NCT03035409. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
ClinicalTrials.gov study NCT04683939. IPD Sharing: NO. Countries: 2. Publications: 1.
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
ClinicalTrials.gov study NCT03087591. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
ClinicalTrials.gov study NCT02115828. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
ClinicalTrials.gov study NCT02111863. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
ClinicalTrials.gov study NCT03668119. IPD Sharing: NO. Countries: 17. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.